title: High-dose, short-duration cisplatin/doxorubicin combination chemotherapy for advanced ovarian epithelial cancer.
abstract: Sixty-one patients with epithelial ovarian cancer were treated with intensive high-dose, short-course chemotherapy that consisted of cisplatin (120 mg/m2) and doxorubicin (70 mg/m2) every 3 weeks for four cycles. Patients in complete clinical remission were offered second-look laparotomy (SLL). Patients with minimal or no residual disease at SLL were randomized to either cyclophosphamide (1000 mg/m2 every 21 days for six cycles) or whole-abdominal radiation therapy. All patients completed therapy with a median leukocyte nadir 1.3/microliter and platelet nadir of 90/microliters. Forty-five patients (74%) had a complete clinical response. Results of twenty-two of 36 second-look procedures (64%) showed no evidence of disease (NED). After SLL, 19 patients received six courses of cyclophosphamide and 16 patients received whole-abdominal radiation. Nine patient who refused SLL and one patient with negative SLL findings refused additional treatment. The median survival time for all patients was 51.3 months. High-dose intensive chemotherapy regimens have high response rates, but survival needs to be compared with traditional low-dose regimens. Although high-dose cisplatin and doxorubicin were myelosuppressive, the resulting complications were manageable. There was no significant difference between the mean survival times of patients receiving Cytoxan, abdominal radiation, or no treatment as second-line therapy.
authors.affiliation: Department of Obstetrics and Gynecology, University of Massachusetts Medical Center, Worcester 01655.
authors.forename: R E
authors.initials: RE
authors.lastname: Hunter
authors.forename: T W
authors.initials: TW
authors.lastname: Griffin
authors.forename: S
authors.initials: S
authors.lastname: Stevens
authors.forename: L D
authors.initials: LD
authors.lastname: Roman
authors.forename: F
authors.initials: F
authors.lastname: Bokhari
authors.forename: F R
authors.initials: FR
authors.lastname: Reale
authors.forename: W K
authors.initials: WK
authors.lastname: Tak
authors.forename: T J
authors.initials: TJ
authors.lastname: Fitzgerald
authors.forename: M B
authors.initials: MB
authors.lastname: Dillon
authors.forename: P G
authors.initials: PG
authors.lastname: Rose
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use* / Q000633:toxicity; D017024:Chemotherapy, Adjuvant; D002945:Cisplatin / Q000008:administration & dosage* / Q000633:toxicity; D002985:Clinical Protocols; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000627:therapeutic use; D003536:Cystadenocarcinoma / Q000188:drug therapy* / Q000532:radiotherapy; D004317:Doxorubicin / Q000008:administration & dosage* / Q000633:toxicity; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007813:Laparotomy; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced; D011446:Prospective Studies; D012074:Remission Induction; D015996:Survival Rate; D013921:Thrombocytopenia / Q000139:chemically induced
chemical_list: D004317:Doxorubicin; D003520:Cyclophosphamide; D002945:Cisplatin